UCapital NewsBusiness Super App · news connected to data, companies, people and deals
IT
VoicesWire
LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
629
via finance.yahoo.comBusiness & Companies

Lilly says retatrutide delivers greater weight loss than Ozempic in type 2 diabetes adults

FROM THE WIRE · FINANCE.YAHOO.COM

(Updates with Novo Nordisk's comments in the last two paragraphs.) Eli Lilly (LLY) said Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a…

Read at the source ↗
MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishFavorable data versus a rival drug can shift market share expectations in obesity and diabetes drugs.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Eli Lilly said retatrutide delivers greater weight loss than Ozempic.
  2. 02The finding concerns adults with type 2 diabetes.
  3. 03Novo Nordisk commented on the news in the final paragraphs of the article.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Eli Lilly and CompanyLLYStock1,286.13 USD-0.19%today +0.33%Positive Novo Nordisk A/SNVOStock38.06 USD-0.16%today -1.58%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

UCapital News is the news section of UCapital24 S.p.A. All content is for information purposes only and does not constitute financial advice, a recommendation or a solicitation to invest. Even where terms such as “buy”, “sell”, “bullish” or “bearish”, or asset impact signals, appear, they only indicate the possible effect of a news item on the markets and are not an invitation to buy or sell financial instruments. News is analysed with UCapital AI and may also be published via API feeds from third-party providers, to give our users a continuous flow of news. UCapital24 S.p.A. accepts no liability of any kind for decisions made on the basis of this content. Wire releases are published by companies and are not verified by the newsroom.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.